Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
zoom
those 500000 were a buy,me
vol=1,310,70 0
ask=.0092
vol-284,000
NEWS out halb
from the last pr=More news to be issued shortly."
looks like it$$$$$$$$$$$$$$$$$$$$
CORRECTION BY SOURCE: Halberd Corp. Signs Significant Revenue Sharing Agreement with Athena GTX
Press Release | 01/10/2024
Correction: The initial release stated Mr. Peter Croden was previously Global President of Upjohn/Pfizer Animal Health Division in Germany. The Animal Health Division is located in Kalamazoo, Michigan. We are sorry for any confusion this may have caused.
Athena will employ its successful history of securing government contracts, spearheading such initiatives
JACKSON CENTER, PA / ACCESSWIRE / January 10, 2024 / Halberd Corporation (OTC-PINK:HALB) is thrilled to declare the formalization of a profitable revenue-sharing accord with Athena GTX, Inc., of Johnston, Iowa, (www.athenagtx.com). Athena GTX is a private enterprise specializing in providing medical care solutions tailored for first responders in both civilian and government sectors.
Athena's 20+ year history of innovative research and development funding from the government (representing 60% of its income historically) in terms of multi-year contracts and grants, and specifically, novel military products and services averaged about $4-5 million per year with substantial growth still ongoing in these markets. This agreement aligns Athena GTX's proven expertise and vast connections with breakthrough Intellectual property owned by Halberd. Together, their 2024 aggressive development plans include rapid release of products into a market Halberd has not been able to tap into for both Halberd's innovative Traumatic Brain Injury (TBI) nasal spray therapy and LDN+ for Post Traumatic Stress Disorder (PTSD), suicidal ideation, pain, anxiety, and drug/alcohol addiction common in returning veterans. This, according to new highly exciting government proposals, suggests an enormously exciting year ahead, particularly with the feedback received from these agencies.
Dr. Mark Darrah, CEO of Athena, stated; "The combination of ongoing University research on Halberd's unique concept products today, with very credible preliminary results, and the enormous market demands we serve, is a natural win-win for both companies. Our plan is to bolster funding in these efforts, capture new research dollars from the government, and push the technology solutions through the FDA and into vertical markets expeditiously. These product solutions dovetail nicely into what we do now and whom we serve. I could not be more pleased!
Recent business analyses detailed our five-year plan forward documenting a compelling market demand and overall an $80 billion potential diversified market expanding at impressive annual growth rates. With Athena's 2024-2026 revenue projections nearly doubling, the Athena partnership with Halberd now represents unparalleled growth projections for both companies."
Peter Croden, Chairman of the Board of CrodenHealth Corp. (another new joint venture partner of Halberd) and former President of Upjohn/Pfizer Canada as well as later Global President of Upjohn/Pfizer Animal Health Division, headquartered in Kalamazoo Michigan, stated, "CrodenHealth Corp. is looking forward to a very successful relationship with Athena GTX and the Halberd Corporation. And, yes, it is going to be a great year in 2024!!."
William A. Hartman, Chairman, President and CEO of Halberd Corporation, added, "Beginning 2023, the task ahead looked daunting- - Halberd needed seven key elements in order to seriously plan for future commercial applications for our technology products, and these were:
Research funding for our base antibody/antigen experimentation at Youngstown State University;
Research funding for our continuing animal testing at Mississippi State University;
Funding for potential clinical trials of our patented LDN+ drug and our patent-pending TBI nasal spray;
Funding for potential FDA certification testing of both products;
Knowledge of how to work with the military and a reputation as a qualified supplier with the purchasing agents at the military agencies;
Experience in launching biomedical products into the market; and
Contacts with Big Pharma for potential future ventures and a potential eventual lucrative buyout.
I can safely say that we have secured all of the desired elements with our newly announced ventures with CrodenHealth Corp and Athena GTX. It has taken many months to put this master plan into form, but we have finally assembled the perfect team. We expect great things to happen rather quickly in 2024 because some of the advanced steps have already been initiated. More news to be issued shortly."
To get the latest
on Halberd's exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/).
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About Athena GTX, Inc.
Athena GTX is a certified DoD small business with Corporate Headquarters in Johnston, Iowa. Athena focuses development on wearables and highly mobile, wirelessly connected monitoring technologies, and transitioning those to key markets to meet unmet needs of first responders worldwide. Wireless Patient Monitoring - Athena GTX connects patient and provider About - Athena GTX® Inc.
About CrodenHealth Corp
"We help scale amazing companies!"SM
CrodenHealth Corp. is a powerful modern team in healthcare. CrodenHealth Corp ensures clients achieve profitable growth through branding, strategic marketing, & tailored go to market strategies. With an exceptional team of marketing and industry experts, we collaborate with our clients to develop or optimize strategies and support successful implementation while maximizing return on investment (ROI).
See: http://crodenhealth.com/
About Halberd Corporation.
Halberd Corporation (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed 22 related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Company' cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are
arket Cap Market Cap
5,858,748
01/09/2024
yes it is$$$$$$$$$$$$$
BUSINESS DESCRIPTION,halb
Halberd Corp is a research-based company seeking to develop treatments for a range of diseases. Their extracorporeal method treats blood-borne, neurological and infectious diseases. Halberd's patents remove bodily fluids in a continuous fashion, like dialysis, or in a batch process. To treat the specific disease, the treatment is applied to the bodily fluid extracorporeally, or outside the body. Disease eradication occurs when designed disease-specific antibodies conjoined with metallic nanoparticles come in contact with disease antigens, and the resultant conjoined antibody/nanoparticle/antigen moiety are then exposed to radio frequency, laser irradiation, or chemical bonding and are destroyed. The cleansed bodily fluids are then returned to the patient without deadly side effects associated with injected or ingested medications.Halberd's technology base consists of four issued patents and 22 pending patents: Projects with potential submission to government/military agencies include: * Extracorporeal eradication of inflammatory cytokines from cerebrospinal fluid associated with PTSD and Suicidal Ideation * Therapeutic lozenges to alleviate pain and anxiety as well as chemical and alcohol addiction * Eradication of antibiotic-resistant bacteria and deadly Candida Auris fungi supplied by CDC * Development of a nasal spray is in pre-clinical testing designed to eliminate neurodegenerative cascade associated of head trauma
BUSINESS DESCRIPTION,halb
Halberd Corp is a research-based company seeking to develop treatments for a range of diseases. Their extracorporeal method treats blood-borne, neurological and infectious diseases. Halberd's patents remove bodily fluids in a continuous fashion, like dialysis, or in a batch process. To treat the specific disease, the treatment is applied to the bodily fluid extracorporeally, or outside the body. Disease eradication occurs when designed disease-specific antibodies conjoined with metallic nanoparticles come in contact with disease antigens, and the resultant conjoined antibody/nanoparticle/antigen moiety are then exposed to radio frequency, laser irradiation, or chemical bonding and are destroyed. The cleansed bodily fluids are then returned to the patient without deadly side effects associated with injected or ingested medications.Halberd's technology base consists of four issued patents and 22 pending patents: Projects with potential submission to government/military agencies include: * Extracorporeal eradication of inflammatory cytokines from cerebrospinal fluid associated with PTSD and Suicidal Ideation * Therapeutic lozenges to alleviate pain and anxiety as well as chemical and alcohol addiction * Eradication of antibiotic-resistant bacteria and deadly Candida Auris fungi supplied by CDC * Development of a nasal spray is in pre-clinical testing designed to eliminate neurodegenerative cascade associated of head trauma
lb.
BUSINESS DESCRIPTION
Halberd Corp is a research-based company seeking to develop treatments for a range of diseases. Their extracorporeal method treats blood-borne, neurological and infectious diseases. Halberd's patents remove bodily fluids in a continuous fashion, like dialysis, or in a batch process. To treat the specific disease, the treatment is applied to the bodily fluid extracorporeally, or outside the body. Disease eradication occurs when designed disease-specific antibodies conjoined with metallic nanoparticles come in contact with disease antigens, and the resultant conjoined antibody/nanoparticle/antigen moiety are then exposed to radio frequency, laser irradiation, or chemical bonding and are destroyed. The cleansed bodily fluids are then returned to the patient without deadly side effects associated with injected or ingested medications.Halberd's technology base consists of four issued patents and 22 pending patents: Projects with potential submission to government/military agencies include: * Extracorporeal eradication of inflammatory cytokines from cerebrospinal fluid associated with PTSD and Suicidal Ideation * Therapeutic lozenges to alleviate pain and anxiety as well as chemical and alcohol addiction * Eradication of antibiotic-resistant bacteria and deadly Candida Auris fungi supplied by CDC * Development of a nasal spray is in pre-clinical testing designed to eliminate neurodegenerative cascade associated of head trauma
OTC DISCLOSURE & NEWS SERVICE
Halberd Corporation Signs Multi-Faceted Agreement with CrodenHealth.com
Press Release | 12/13/2023
Peter Croden, CrodenHealth Chairman, previously executive with Pharmacia & Upjohn (Pfizer), Upjohn Canada, Upjohn Global Animal Health, NephRx, and Parnell Pharmaceuticals Holdings, Ltd. Endeavors to move Halberd forward
JACKSON CENTER, PA / ACCESSWIRE / December 13, 2023 / Halberd Corporation (OTC PINK:HALB) and CrodenHealth.com of Canada agree to produce, market, sell and distribute Halberd's patented low dose naltrexone combo product(s) worldwide. The agreement also allows CrodenHealth.com right of first refusal regarding similar rights to future products in Halberd's development pipeline.
Peter Croden, Chairman of the Board of CrodenHealth, enjoys a long history in the pharmaceutical industry- over 30 years with Upjohn & Pharmacia Corp. (now Pfizer) in various senior management roles, including President and General Manager of Upjohn Canada and later, President Upjohn Worldwide Animal Health. In 2001, Mr. Croden launched the biotechnology company, NephRx as CEO. In 2015, Mr Croden was appointed to the Board of Parnell Pharmaceuticals Holdings, Ltd.
Peter Croden, together with his son, Brad Croden, and nephew, Todd Croden, have over five decades of experience in the pharmaceuticals industry, culminating in the management of CrodenHealth.com. CrodenHealth's role with Halberd Corporation will include efforts to facilitate industry joint ventures and funding as well as drug certification efforts.
Brad Croden, CEO of CrodenHealth, commented, "We are excited to monetize the amazing current & future intellectual property (products) of Halberd Corporation; creating new & profitable revenue streams. This new agreement marks the beginning of a long fruitful win-win relationship between CrodenHealth & Halberd Corporation."
Peter Croden added, "With CrodenHealth's vast pharmaceutical sales & marketing expertise and Halberd Corporations unique groundbreaking intellectual property & first-to-market products - will ensure a profitable positive impact on patient outcomes."
William A. Hartman, Chairman, President, and CEO of Halberd Corporation, commented, "Given the commitment of CrodenHealth, coupled with the principals' vast network of relationships and past dealings with large pharmaceutical companies, they have the wherewithal to facilitate game changing joint ventures. These relationships, should also inure to the benefit of Athena GTX and complements many of Halberd's other efforts in the medical field. They also enhance Halberd's capacity to fulfill its commitments to the various military organizations which have specifically expressed interest in one or more of Halberd's endeavors. CrodenHealth also has access to unique applications of bio-marker artificial intelligence in various medical applications."
To stay updated on the latest developments from Halberd, subscribe by submitting this form. (https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter: @HalberdC
About CrodenHealth.com
"We help scale amazing companies!"SM
CrodenHealth is a powerful modern team in healthcare. CrodenHealth ensures clients achieve profitable growth through branding, strategic marketing, & tailored go to market strategies. With an exceptional team of marketing and industry experts, we collaborate with our clients to develop or optimize strategies and support successful implementation while maximizing return on investment (ROI).
See: http://crodenhealth.com/
About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), a publicly traded entity on the OTC Market, adheres fully to OTC Market reporting regulations. Following its restructuring in April 2020, Halberd secured exclusive global rights to three granted patents and submitted 22 associated provisional, PCT, or utility patent
Hheres something about batteriesOTC DISCLOSURE & NEWS SERVICE
Premier Biomedical Inc. (OTC-PINK: “BIEI“), now known as Premier Graphene, Inc., collaborates with Oklahoma Based “Biographene Technology Inc”, for its Graphene Production.
Press Release | 03/16/2023
Premier Biomedical Inc. (OTC-PINK: "BIEI"), now known as Premier Graphene, Inc., collaborates with Oklahoma Based "Biographene Technology Inc", for its Graphene Production.
These graphene products, manufactured by Biographene Technology, its proprietary Multi-wall Carbon Nanotubes (MWCNTs) sourced from Hemp Fiber for a high-grade production capacity of five tons per week of graphene.
March 16, 2023 Premier Biomedical Inc., now known as Premier Graphene, Inc. (OTC-PINK: BIEI), relocating to Imperial Valley CA, announces its acquisition of a partial ownership in Oklahoma Based Biographene Technology Inc, https://www.biographenetechnologyinc.com/. An innovativeleader in the bio graphene industry, headed by its chief scientist, Michael McDonnough.
Premier Graphene Inc focuses on cost-effective, green technology of scientific applications, including hemp-basedgraphene enhanced formulations for a myriad of biomedical, commercial and military applications. These applications include: concrete, asphalt, 3D printing filaments, ballistic armor, UHMW polyethylene, an anti-viral / anti-bacterial multi-surface coating, fireproof polyurethane insulation expansion foams, anti-abrasion coatings, and neat & recycled PET, HDPE, and other polymers. Its partner in pursuit of these applications is Oklahoma Based Biographene Technology Inc. After weeks of due diligence and negotiation, we have reached an agreementreports Premier Graphene Inc senior consultant Pedro Mendezand brother of CEO Ivan Mendez.
Ivan Mendez CEO of Premier Graphene Inc. explains Premier Graphene and its officers and directors welcomeBiographeneTechnology Inc.s CEO, Adam Havig and its chief scientist in charge of product development, Michael McDonnough to our family. With them on board, we have most of the pieces needed for the most technical part of graphene production in North America. Separately, Premier Graphene, Inc. will be securing the raw materials, hemp, for the high-grade production of graphene. I believe that this association will provide us with yet another critical piece that we can employ for a successful endeavor in this burgeoning, incredibly efficacious arena.
Adam Havig, CEO of Biographene Technology Inc., added, We are excited to partner with the Premier Graphene Inc. With this agreement, we can further meet our goals as becoming one of the industrys premier leaders in the graphene and bio-graphite replacement market. Within the next year, we expect our production facility to be able to produce up to 15,000 tons per year.
Premier Graphene Incs production program will be an eco-friendly, sustainable and cost-effective process. They are designed to be bio-enhanced/bio-beneficial (more than just eco-friendly but carbon negative) products. Such products will include graphene-enhanced concrete, superconductive graphene products and electric batteries with enhanced capacity. They will also be lightweight in order to achieve certain unparalleled benefits, including for electric vehicles, aerospace, military and other commercial applications. Epidemiologic Solutions Corporation, a public charity, is donating $150,000, for no consideration. This will enable Premier Graphene to own 10% of Biographene Technology. More importantly, however, it will enable both to acquire, used equipment and repurpose it at a collective cost of approximately 10% of the cost if acquired unused. We will be able to acquire low cost, but highly suitable hemp as the raw material for a high-grade and highly efficacious, most suitable form of graphene possible. Ultimately, with this talented scientific team we are confident that these strategies will result in high quality, highly innovative, products at a more reasonable price in this highly competitive market.
OTC DISCLOSURE & NEWS SERVICE
Premier Biomedical Inc. (OTC-PINK: “BIEI“), now known as Premier Graphene, Inc., collaborates with Oklahoma Based “Biographene Technology Inc”, for its Graphene Production.
Press Release | 03/16/2023
Premier Biomedical Inc. (OTC-PINK: "BIEI"), now known as Premier Graphene, Inc., collaborates with Oklahoma Based "Biographene Technology Inc", for its Graphene Production.
These graphene products, manufactured by Biographene Technology, its proprietary Multi-wall Carbon Nanotubes (MWCNTs) sourced from Hemp Fiber for a high-grade production capacity of five tons per week of graphene.
March 16, 2023 Premier Biomedical Inc., now known as Premier Graphene, Inc. (OTC-PINK: BIEI), relocating to Imperial Valley CA, announces its acquisition of a partial ownership in Oklahoma Based Biographene Technology Inc, https://www.biographenetechnologyinc.com/. An innovativeleader in the bio graphene industry, headed by its chief scientist, Michael McDonnough.
Premier Graphene Inc focuses on cost-effective, green technology of scientific applications, including hemp-basedgraphene enhanced formulations for a myriad of biomedical, commercial and military applications. These applications include: concrete, asphalt, 3D printing filaments, ballistic armor, UHMW polyethylene, an anti-viral / anti-bacterial multi-surface coating, fireproof polyurethane insulation expansion foams, anti-abrasion coatings, and neat & recycled PET, HDPE, and other polymers. Its partner in pursuit of these applications is Oklahoma Based Biographene Technology Inc. After weeks of due diligence and negotiation, we have reached an agreementreports Premier Graphene Inc senior consultant Pedro Mendezand brother of CEO Ivan Mendez.
Ivan Mendez CEO of Premier Graphene Inc. explains Premier Graphene and its officers and directors welcomeBiographeneTechnology Inc.s CEO, Adam Havig and its chief scientist in charge of product development, Michael McDonnough to our family. With them on board, we have most of the pieces needed for the most technical part of graphene production in North America. Separately, Premier Graphene, Inc. will be securing the raw materials, hemp, for the high-grade production of graphene. I believe that this association will provide us with yet another critical piece that we can employ for a successful endeavor in this burgeoning, incredibly efficacious arena.
Adam Havig, CEO of Biographene Technology Inc., added, We are excited to partner with the Premier Graphene Inc. With this agreement, we can further meet our goals as becoming one of the industrys premier leaders in the graphene and bio-graphite replacement market. Within the next year, we expect our production facility to be able to produce up to 15,000 tons per year.
Premier Graphene Incs production program will be an eco-friendly, sustainable and cost-effective process. They are designed to be bio-enhanced/bio-beneficial (more than just eco-friendly but carbon negative) products. Such products will include graphene-enhanced concrete, superconductive graphene products and electric batteries with enhanced capacity. They will also be lightweight in order to achieve certain unparalleled benefits, including for electric vehicles, aerospace, military and other commercial applications. Epidemiologic Solutions Corporation, a public charity, is donating $150,000, for no consideration. This will enable Premier Graphene to own 10% of Biographene Technology. More importantly, however, it will enable both to acquire, used equipment and repurpose it at a collective cost of approximately 10% of the cost if acquired unused. We will be able to acquire low cost, but highly suitable hemp as the raw material for a high-grade and highly efficacious, most suitable form of graphene possible. Ultimately, with this talented scientific team we are confident that these strategies will result in high quality, highly innovative, products at a more reasonable price in this highly competitive market.
1 agree, got me 300000 more,i dont think there r many shares available out there,will see
i have some shares,how do i sell,give me a web-site,thank u i am new to this got some free shares about 2 yrs ago,i am completely loss here
i have some shares,how do i sell,give me a web-site,thank u i am new to this got some free shares about 2 yrs ago,i am completely loss here
how do i sell bitcoin
i didnt say when now did i,but one thing u can count on its coming so u better buy some before its to late
$HALB Halberd and Athena GTX Collaborate on Advanced Traumatic Brain Injury (TBI) Monitoring and Applications for Government Contracts
https://www.accesswire.com/785790/halberd-and-athena-gtx-collaborate-on-advanced-traumatic-brain-injury-tbi-monitoring-and-applications-for-government-contracts
HALB Quote
Detailed Quote Discussion Board
Logo for quote
HALB
Halberd Corp (PK)
0.011
0.0015 (15.79%)
Volume
$HALB Halberd and Athena GTX Collaborate on Advanced Traumatic Brain Injury (TBI) Monitoring and Applications for Government Contracts
https://www.accesswire.com/785790/halberd-and-athena-gtx-collaborate-on-advanced-traumatic-brain-injury-tbi-monitoring-and-applications-for-government-contracts
HALB Quote
Detailed Quote Discussion Board
Logo for quote
HALB
Halberd Corp (PK)
0.011
0.0015 (15.79%)
Volume
$HALB Halberd and Athena GTX Collaborate on Advanced Traumatic Brain Injury (TBI) Monitoring and Applications for Government Contracts
https://www.accesswire.com/785790/halberd-and-athena-gtx-collaborate-on-advanced-traumatic-brain-injury-tbi-monitoring-and-applications-for-government-contracts
HALB Quote
Detailed Quote Discussion Board
Logo for quote
HALB
Halberd Corp (PK)
0.011
0.0015 (15.79%)
Volume
$HALB Halberd and Athena GTX Collaborate on Advanced Traumatic Brain Injury (TBI) Monitoring and Applications for Government Contracts
https://www.accesswire.com/785790/halberd-and-athena-gtx-collaborate-on-advanced-traumatic-brain-injury-tbi-monitoring-and-applications-for-government-contracts
HALB Quote
Detailed Quote Discussion Board
Logo for quote
HALB
Halberd Corp (PK)
0.011
0.0015 (15.79%)
Volume
its gona blow up like a atomic bomb,bomb,BOMB,$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
i did boom,BOOM
halbPost#
25835
of 25835
$HALB Halberd and Athena GTX Collaborate on Advanced Traumatic Brain Injury (TBI) Monitoring and Applications for Government Contracts
https://www.accesswire.com/785790/halberd-and-athena-gtx-collaborate-on-advanced-traumatic-brain-injury-tbi-monitoring-and-applications-for-government-contracts
JACKSON CENTER, PA / ACCESSWIRE / September 20, 2023 / Halberd Corporation (OTC PINK:HALB) and Athena GTX, Inc, of Johnston, Iowa commenced collaboration on critical development of submissions for government contracts seeking proposals for the detection and treatment of traumatic brain injury (TBI). The initial focus will be on accelerating and fine-tuning Halberd's proprietary nasal spray for suppressing the effects of traumatic brain injury (TBI). In addition, consistent with the government request, this will include rapid detection and assessment technologies from Athena as a point of injury (POI) treatment for use by both the military, civilian first responders and contact sports participants.
Halberd's nasal spray treatment is designed to suppress the detrimental cascading generation of excess inflammatory cytokines and neurotransmitters which result from progressive traumatic brain injury. Currently, no other product on the market addresses this need with a combination of 1.) a monoclonal antibody against glutamate, thereby decreasing extracellular glutamate (decreasing the excitatory neurotransmitter), 2.) a paranasal insulin counteracting hyperglycolosis and hyperkalemia allowing cerebral blood flow to keep up with brain oxygen demands after TBI, and 3.) a neurosteroid as a positive allosteric modulator, thereby slowing and inhibiting the binding of ligands to orthosteric binding sites. This acts to decrease metabolic demands, lowers intercranial pressure (ICP) and significantly decreases inflammation.
The collaboration plan is to deploy the novel product as a simple nasal spray as a custom formulation allowing for easy and rapid administration in emergency situations, making it particularly valuable for use by military warfighters in theatre and contact sports participants. The research data to date are demonstrating the synergistic effectiveness of this approach (combo of neuroexcitation, hypermetabolism and inflammation/edema mitigations) in animals. In ongoing preclinical studies with IRB-approved protocols, we are showing exciting early data on efficacy in a rat model and soon will begin sheep studies at Mississippi State University. Results in test animals at zero, three, six and fourteen days after induced TBI impact have produced consistent reductions of two key biomarkers of TBI; a 19% reduction in Neuron Specific Enolase (NSE) and a 51% reduction in levels of Glial Fibrillary Acid Protein (GFAP).
NSE is a biomarker of neuronal damage that has been shown to be a predictor of the ultimate outcome of TBI, and GFAP is an indicator of the induction of neuroinflammation and is also an indicator of neurodegeneration associated with Alzheimer's Disease, Parkinson's Disease, epileptic seizures, etc. Excess quantities of these elements have been linked to permanent changes in the brain associated with not only cognitive dysfunction, but potentially PTSD, suicide ideation, and other neurodegenerative diseases. This link to these other disease states is due to the commonality of the antigens demonstrably associated thereto.
Athena has a long history of government contracting on innovative solutions, and designing and developing miniature monitoring devices for these markets with numerous FDA-cleared devices now on the market for target markets throughout the world.
This partnership represents a significant step towards addressing the long-term health implications associated with traumatic brain injury. By harnessing the power of innovative medical solutions, Halberd and Athena aim to enhance the quality of life for those who have sustained traumatic brain injury.
Bullish
BULLISH
halbPost#
25835
of 25835
$HALB Halberd and Athena GTX Collaborate on Advanced Traumatic Brain Injury (TBI) Monitoring and Applications for Government Contracts
https://www.accesswire.com/785790/halberd-and-athena-gtx-collaborate-on-advanced-traumatic-brain-injury-tbi-monitoring-and-applications-for-government-contracts
JACKSON CENTER, PA / ACCESSWIRE / September 20, 2023 / Halberd Corporation (OTC PINK:HALB) and Athena GTX, Inc, of Johnston, Iowa commenced collaboration on critical development of submissions for government contracts seeking proposals for the detection and treatment of traumatic brain injury (TBI). The initial focus will be on accelerating and fine-tuning Halberd's proprietary nasal spray for suppressing the effects of traumatic brain injury (TBI). In addition, consistent with the government request, this will include rapid detection and assessment technologies from Athena as a point of injury (POI) treatment for use by both the military, civilian first responders and contact sports participants.
Halberd's nasal spray treatment is designed to suppress the detrimental cascading generation of excess inflammatory cytokines and neurotransmitters which result from progressive traumatic brain injury. Currently, no other product on the market addresses this need with a combination of 1.) a monoclonal antibody against glutamate, thereby decreasing extracellular glutamate (decreasing the excitatory neurotransmitter), 2.) a paranasal insulin counteracting hyperglycolosis and hyperkalemia allowing cerebral blood flow to keep up with brain oxygen demands after TBI, and 3.) a neurosteroid as a positive allosteric modulator, thereby slowing and inhibiting the binding of ligands to orthosteric binding sites. This acts to decrease metabolic demands, lowers intercranial pressure (ICP) and significantly decreases inflammation.
The collaboration plan is to deploy the novel product as a simple nasal spray as a custom formulation allowing for easy and rapid administration in emergency situations, making it particularly valuable for use by military warfighters in theatre and contact sports participants. The research data to date are demonstrating the synergistic effectiveness of this approach (combo of neuroexcitation, hypermetabolism and inflammation/edema mitigations) in animals. In ongoing preclinical studies with IRB-approved protocols, we are showing exciting early data on efficacy in a rat model and soon will begin sheep studies at Mississippi State University. Results in test animals at zero, three, six and fourteen days after induced TBI impact have produced consistent reductions of two key biomarkers of TBI; a 19% reduction in Neuron Specific Enolase (NSE) and a 51% reduction in levels of Glial Fibrillary Acid Protein (GFAP).
NSE is a biomarker of neuronal damage that has been shown to be a predictor of the ultimate outcome of TBI, and GFAP is an indicator of the induction of neuroinflammation and is also an indicator of neurodegeneration associated with Alzheimer's Disease, Parkinson's Disease, epileptic seizures, etc. Excess quantities of these elements have been linked to permanent changes in the brain associated with not only cognitive dysfunction, but potentially PTSD, suicide ideation, and other neurodegenerative diseases. This link to these other disease states is due to the commonality of the antigens demonstrably associated thereto.
Athena has a long history of government contracting on innovative solutions, and designing and developing miniature monitoring devices for these markets with numerous FDA-cleared devices now on the market for target markets throughout the world.
This partnership represents a significant step towards addressing the long-term health implications associated with traumatic brain injury. By harnessing the power of innovative medical solutions, Halberd and Athena aim to enhance the quality of life for those who have sustained traumatic brain injury.
Bullish
BULLISH
Post# halb
25835
of 25835
$HALB Halberd and Athena GTX Collaborate on Advanced Traumatic Brain Injury (TBI) Monitoring and Applications for Government Contracts
https://www.accesswire.com/785790/halberd-and-athena-gtx-collaborate-on-advanced-traumatic-brain-injury-tbi-monitoring-and-applications-for-government-contracts
JACKSON CENTER, PA / ACCESSWIRE / September 20, 2023 / Halberd Corporation (OTC PINK:HALB) and Athena GTX, Inc, of Johnston, Iowa commenced collaboration on critical development of submissions for government contracts seeking proposals for the detection and treatment of traumatic brain injury (TBI). The initial focus will be on accelerating and fine-tuning Halberd's proprietary nasal spray for suppressing the effects of traumatic brain injury (TBI). In addition, consistent with the government request, this will include rapid detection and assessment technologies from Athena as a point of injury (POI) treatment for use by both the military, civilian first responders and contact sports participants.
Halberd's nasal spray treatment is designed to suppress the detrimental cascading generation of excess inflammatory cytokines and neurotransmitters which result from progressive traumatic brain injury. Currently, no other product on the market addresses this need with a combination of 1.) a monoclonal antibody against glutamate, thereby decreasing extracellular glutamate (decreasing the excitatory neurotransmitter), 2.) a paranasal insulin counteracting hyperglycolosis and hyperkalemia allowing cerebral blood flow to keep up with brain oxygen demands after TBI, and 3.) a neurosteroid as a positive allosteric modulator, thereby slowing and inhibiting the binding of ligands to orthosteric binding sites. This acts to decrease metabolic demands, lowers intercranial pressure (ICP) and significantly decreases inflammation.
The collaboration plan is to deploy the novel product as a simple nasal spray as a custom formulation allowing for easy and rapid administration in emergency situations, making it particularly valuable for use by military warfighters in theatre and contact sports participants. The research data to date are demonstrating the synergistic effectiveness of this approach (combo of neuroexcitation, hypermetabolism and inflammation/edema mitigations) in animals. In ongoing preclinical studies with IRB-approved protocols, we are showing exciting early data on efficacy in a rat model and soon will begin sheep studies at Mississippi State University. Results in test animals at zero, three, six and fourteen days after induced TBI impact have produced consistent reductions of two key biomarkers of TBI; a 19% reduction in Neuron Specific Enolase (NSE) and a 51% reduction in levels of Glial Fibrillary Acid Protein (GFAP).
NSE is a biomarker of neuronal damage that has been shown to be a predictor of the ultimate outcome of TBI, and GFAP is an indicator of the induction of neuroinflammation and is also an indicator of neurodegeneration associated with Alzheimer's Disease, Parkinson's Disease, epileptic seizures, etc. Excess quantities of these elements have been linked to permanent changes in the brain associated with not only cognitive dysfunction, but potentially PTSD, suicide ideation, and other neurodegenerative diseases. This link to these other disease states is due to the commonality of the antigens demonstrably associated thereto.
Athena has a long history of government contracting on innovative solutions, and designing and developing miniature monitoring devices for these markets with numerous FDA-cleared devices now on the market for target markets throughout the world.
This partnership represents a significant step towards addressing the long-term health implications associated with traumatic brain injury. By harnessing the power of innovative medical solutions, Halberd and Athena aim to enhance the quality of life for those who have sustained traumatic brain injury.
Bullish
BULLISH
i think he said2040
good news wont be long,$$$$$$$$$$$$$$$$$$$$$
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
September 14 2023 - 04:01PM
Edgar (US Regulatory)
Alert
Print
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(MARK ONE)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended July 31, 2023
or
[_] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _________ to _________
Commission File Number: 0-55077
NEUTRA CORP.
(Exact name of registrant as specified in its charter)
Wyoming 27-4505461
(State or other jurisdiction of Incorporation or organization) (I.R.S. Employer Identification Number)
54 Sugar Creek Center Blvd., Suite 200
Sugar Land, Texas 77478
(Address of principal executive offices) (Zip code)
Registrant’s telephone number, including area code: 702-793-4121
Securities registered pursuant to Section 12(b) of the Act: None
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
[X] Yes [_] No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
[X] Yes [_] No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer [_] Accelerated filer [_]
Non-accelerated filer [X] Smaller reporting company [X]
Emerging growth company [_]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [_]
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
[_] Yes [X] No
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. As of September 11, 2023, 2,917,899,124 shares of common stock are issued and outstanding.
TABLE OF CONTENTS
PART I — FINANCIAL INFORMATION
Item 1. Financial Statements 4
Consolidated Balance Sheets (unaudited) 4
Consolidated Statements of Operations (unaudited) 5
Consolidated Statements of Stockholders’ Deficit (unaudited) 6
Consolidated Statement of Changes in Mezzanine Equity(unaudited) 7
Consolidated Statements of Cash Flows (unaudited) 8
Notes to the Unaudited Consolidated Financial Statements 9
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 14
Item 3. Quantitative and Qualitative Disclosures about Market Risk 16
Item 4. Controls and Procedures 16
PART II — OTHER INFORMATION
Item 1. Legal Proceedings 17
Item 1A. Risk Factors 17
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 17
Item 3. Defaults upon Senior Securities 17
Item 4. Mine Safety Disclosures 17
Item 5. Other Information 17
Item 6. Exhibits 17
Signatures 18
- 2 -
Table of Contents
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
Certain statements in this report contain or may contain forward-looking statements. These statements, identified by words such as “plan”, “anticipate”, “believe”, “estimate”, “should”, “expect” and similar expressions include our expectations and objectives regarding our future financial position, operating results and business strategy. These statements are subject to known and unknown risks, uncertainties and other factors, which may cause actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward - looking statements. These forward-looking statements were based on various factors and were derived utilizing numerous assumptions and other factors that could cause our actual results to differ materially from those in the forward-looking statements. These factors include, but are not limited to, our ability to secure suitable financing to continue with our existing business or change our business and conclude a merger, acquisition or combination with a business prospect, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk, U.S. and global competition, and other factors. Most of these factors are difficult to predict accurately and are generally beyond our control. You should consider the areas of risk described in connection with any forward-looking statements that may be made herein. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Readers should carefully review this report in its entirety, including but not limited to our financial statements and the notes thereto and the risks described in our Annual Report on Form 10-K for the fiscal year ended January 31, 2023. We advise you to carefully review the reports and documents we file from time to time with the Securities and Exchange Commission (the “SEC”), particularly our quarterly reports on Form 10-Q and our current reports on Form 8-K. Except for our ongoing obligations to disclose material information under the Federal securities laws, we undertake no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.
OTHER PERTINENT INFORMATION
When used in this report, the terms, “we,” the “Company,” “our,” and “us” refers to Neutra Corp., a Wyoming corporation.
- 3 -
Table of Contents
PART I — FINANCIAL INFORMATION
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
September 14 2023 - 04:01PM
Edgar (US Regulatory)
Alert
Print
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(MARK ONE)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended July 31, 2023
or
[_] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _________ to _________
Commission File Number: 0-55077
NEUTRA CORP.
(Exact name of registrant as specified in its charter)
Wyoming 27-4505461
(State or other jurisdiction of Incorporation or organization) (I.R.S. Employer Identification Number)
54 Sugar Creek Center Blvd., Suite 200
Sugar Land, Texas 77478
(Address of principal executive offices) (Zip code)
Registrant’s telephone number, including area code: 702-793-4121
Securities registered pursuant to Section 12(b) of the Act: None
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
[X] Yes [_] No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
[X] Yes [_] No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer [_] Accelerated filer [_]
Non-accelerated filer [X] Smaller reporting company [X]
Emerging growth company [_]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [_]
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
[_] Yes [X] No
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. As of September 11, 2023, 2,917,899,124 shares of common stock are issued and outstanding.
TABLE OF CONTENTS
PART I — FINANCIAL INFORMATION
Item 1. Financial Statements 4
Consolidated Balance Sheets (unaudited) 4
Consolidated Statements of Operations (unaudited) 5
Consolidated Statements of Stockholders’ Deficit (unaudited) 6
Consolidated Statement of Changes in Mezzanine Equity(unaudited) 7
Consolidated Statements of Cash Flows (unaudited) 8
Notes to the Unaudited Consolidated Financial Statements 9
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 14
Item 3. Quantitative and Qualitative Disclosures about Market Risk 16
Item 4. Controls and Procedures 16
PART II — OTHER INFORMATION
Item 1. Legal Proceedings 17
Item 1A. Risk Factors 17
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 17
Item 3. Defaults upon Senior Securities 17
Item 4. Mine Safety Disclosures 17
Item 5. Other Information 17
Item 6. Exhibits 17
Signatures 18
- 2 -
Table of Contents
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
Certain statements in this report contain or may contain forward-looking statements. These statements, identified by words such as “plan”, “anticipate”, “believe”, “estimate”, “should”, “expect” and similar expressions include our expectations and objectives regarding our future financial position, operating results and business strategy. These statements are subject to known and unknown risks, uncertainties and other factors, which may cause actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward - looking statements. These forward-looking statements were based on various factors and were derived utilizing numerous assumptions and other factors that could cause our actual results to differ materially from those in the forward-looking statements. These factors include, but are not limited to, our ability to secure suitable financing to continue with our existing business or change our business and conclude a merger, acquisition or combination with a business prospect, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk, U.S. and global competition, and other factors. Most of these factors are difficult to predict accurately and are generally beyond our control. You should consider the areas of risk described in connection with any forward-looking statements that may be made herein. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Readers should carefully review this report in its entirety, including but not limited to our financial statements and the notes thereto and the risks described in our Annual Report on Form 10-K for the fiscal year ended January 31, 2023. We advise you to carefully review the reports and documents we file from time to time with the Securities and Exchange Commission (the “SEC”), particularly our quarterly reports on Form 10-Q and our current reports on Form 8-K. Except for our ongoing obligations to disclose material information under the Federal securities laws, we undertake no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.
OTHER PERTINENT INFORMATION
When used in this report, the terms, “we,” the “Company,” “our,” and “us” refers to Neutra Corp., a Wyoming corporation.
- 3 -
Table of Contents
PART I — FINANCIAL INFORMATION
boom,BOOM,
halb-news today=Astounding Early Test Results of Halberd's Traumatic Brain Injury (TBI) Project at Mississippi State University (MSU)
Press Release | 09/06/2023
Anecdotal Results of Halberd's Nasal Spray Reveals Demonstrably Significant Reduction of Traumatic Brain Injury Markers
JACKSON CENTER, PA / ACCESSWIRE / September 6, 2023 / Halberd Corporation's (OTC PINK:HALB) research at Mississippi State University (MSU) has shown significant reduction in two key markers of traumatic brain injury (TBI) in early testing of Halberd's patent-pending nasal spray to mitigate the effects of TBI. Anecdotal data in preliminary testing reveals a 20% reduction in Neuron Specific Enolase and a 50% reduction in the levels of Glial Fibrillary Acid Protein compared to the control group.
Neuron Specific Enolase (NSE) is a biomarker of neuronal damage that has been shown to be a predictor of the ultimate outcomes of TBI. Glial Fibrillary Acid Protein (GFAP) is an indicator of the induction of neuroinflammation and is increased following traumatic brain injury. It is also thought to be an indicator of ongoing neurodegeneration related to numerous other diseases, Reductions of NSE and GFAP are associated with better neurological outcomes from head trauma.
Dr. Russell Carr, professor at Mississippi State University Veterinary College and lead investigator, stated, "The research testing the effectiveness of the novel nasal therapeutic to treat the negative effects induced by traumatic brain injury has made significant progress. At this point, we have completed the impacts and have collected tissues. While the analysis of all regions is not complete, the results for the cerebral cortex strongly suggest that nasal administration of the therapeutic following a significant head impact greatly reduces the markers for cellular damage and neuroinflammation. These data are not complete as we intend to analyze the hippocampus as well as plan to repeat the experiment to ensure scientific validity."
Mitchell S. Felder, M.D., Halberd's Chief Technology Officer, noted, "These are very exciting preliminary results. To the best of my knowledge, this is the only documented therapeutic pathophysiologic ameliorations for traumatic brain injury. This may also have a great deal of utility in the treatment of brain tumors, strokes and epilepsy, besides possibly preventing the development of cognitive dysfunction, seizures and TBI clinical symptomatology in head trauma."
William A. Hartman, Chairman, President and CEO of Halberd Corporation, remarked, "The breakthrough testing to date at MSU is showing the timely application of Halberd's nasal spray within hours of a traumatic brain injury can potentially mitigate factors associated with long-term neurodegeneraton, often leading to Alzheimer's Disease, Parkinson's Disease, Epileptic seizures, PTSD, etc. We expect to fine tune and complete the current testing protocol as well as cognitive testing before commencing such treatment on larger animals. We look forward to relaying these results to the CDC, ARPA-H, DARPA and our Congressman. Communication with the FDA will be coordinated by mdi Consultants, Inc. to ensure the most expeditious review.
"This product could have massive benefit to contact sports participants, such as football, hockey, and soccer, as well as the military and PTSD victims, and reduce the 50,000 depression-related suicides each year in the United States. This product has been shown to be truly revolutionary in early testing. We are committed to completing the pre-clinical testing at MSU to fully demonstrate the medical benefits of this product."
To get the latest news on Halberd's exciting developments, subscribe by submitting this.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About Mississippi State University College of Veterinary Medicine (CVM).
Mississippi State University College of Veterinary Medicine (MSU CVM) was founded in 1974 The CVM has a total of six locations and serves all 82 counties in Mississippi as well as the entire Southeastern United States. The College's main campus is in Starkville and includes the Wise Center, which houses its main teaching hospital, the Animal Health Center. The MSU CVM Department of Comparative Biomedical Sciences faculty and staff represent the basic scientific disciplines required for education of veterinarians. MSU CVM is committed to an ethical approach to treating animals with a genuine passion and drive.
About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed 22 related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Company' cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could differ materially from current projections or
HALB-news today-Astounding Early Test Results of Halberd's Traumatic Brain Injury (TBI) Project at Mississippi State University (MSU)
Press Release | 09/06/2023
Anecdotal Results of Halberd's Nasal Spray Reveals Demonstrably Significant Reduction of Traumatic Brain Injury Markers
JACKSON CENTER, PA / ACCESSWIRE / September 6, 2023 / Halberd Corporation's (OTC PINK:HALB) research at Mississippi State University (MSU) has shown significant reduction in two key markers of traumatic brain injury (TBI) in early testing of Halberd's patent-pending nasal spray to mitigate the effects of TBI. Anecdotal data in preliminary testing reveals a 20% reduction in Neuron Specific Enolase and a 50% reduction in the levels of Glial Fibrillary Acid Protein compared to the control group.
Neuron Specific Enolase (NSE) is a biomarker of neuronal damage that has been shown to be a predictor of the ultimate outcomes of TBI. Glial Fibrillary Acid Protein (GFAP) is an indicator of the induction of neuroinflammation and is increased following traumatic brain injury. It is also thought to be an indicator of ongoing neurodegeneration related to numerous other diseases, Reductions of NSE and GFAP are associated with better neurological outcomes from head trauma.
Dr. Russell Carr, professor at Mississippi State University Veterinary College and lead investigator, stated, "The research testing the effectiveness of the novel nasal therapeutic to treat the negative effects induced by traumatic brain injury has made significant progress. At this point, we have completed the impacts and have collected tissues. While the analysis of all regions is not complete, the results for the cerebral cortex strongly suggest that nasal administration of the therapeutic following a significant head impact greatly reduces the markers for cellular damage and neuroinflammation. These data are not complete as we intend to analyze the hippocampus as well as plan to repeat the experiment to ensure scientific validity."
Mitchell S. Felder, M.D., Halberd's Chief Technology Officer, noted, "These are very exciting preliminary results. To the best of my knowledge, this is the only documented therapeutic pathophysiologic ameliorations for traumatic brain injury. This may also have a great deal of utility in the treatment of brain tumors, strokes and epilepsy, besides possibly preventing the development of cognitive dysfunction, seizures and TBI clinical symptomatology in head trauma."
William A. Hartman, Chairman, President and CEO of Halberd Corporation, remarked, "The breakthrough testing to date at MSU is showing the timely application of Halberd's nasal spray within hours of a traumatic brain injury can potentially mitigate factors associated with long-term neurodegeneraton, often leading to Alzheimer's Disease, Parkinson's Disease, Epileptic seizures, PTSD, etc. We expect to fine tune and complete the current testing protocol as well as cognitive testing before commencing such treatment on larger animals. We look forward to relaying these results to the CDC, ARPA-H, DARPA and our Congressman. Communication with the FDA will be coordinated by mdi Consultants, Inc. to ensure the most expeditious review.
"This product could have massive benefit to contact sports participants, such as football, hockey, and soccer, as well as the military and PTSD victims, and reduce the 50,000 depression-related suicides each year in the United States. This product has been shown to be truly revolutionary in early testing. We are committed to completing the pre-clinical testing at MSU to fully demonstrate the medical benefits of this product."
To get the latest news on Halberd's exciting developments, subscribe by submitting this.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About Mississippi State University College of Veterinary Medicine (CVM).
Mississippi State University College of Veterinary Medicine (MSU CVM) was founded in 1974 The CVM has a total of six locations and serves all 82 counties in Mississippi as well as the entire Southeastern United States. The College's main campus is in Starkville and includes the Wise Center, which houses its main teaching hospital, the Animal Health Center. The MSU CVM Department of Comparative Biomedical Sciences faculty and staff represent the basic scientific disciplines required for education of veterinarians. MSU CVM is committed to an ethical approach to treating animals with a genuine passion and drive.
About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed 22 related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Company' cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could differ materially from current projections or
HALB-Halberd’s Successful Completion of Sampling Phase Marks Major Milestone for Project at Mississippi State University (MSU)
Press Release | 08/22/2023
Novel Nasal Spray for Traumatic Brain Injury Effects Poised to Demonstrate Efficacy in Patent-Pending Product
JACKSON CENTER, PA / ACCESSWIRE / August 22, 2023 / Halberd Corporation (OTC PINK:HALB) announced Mississippi State University (MSU) has finalized the collection of tissue samples from a quantity of the planned test subjects. This enables MSU to proceed with its pre-clinical model to study endpoints for Halberd's groundbreaking patent-pending nasal spray's ability to mitigate the effects of traumatic brain injury (TBI). The analysis of these tissue samples can now proceed to examine and quantify the presence of certain markers related to brain damage and to assess the effectiveness of the nasal spray treatment. The nasal spray is designed to eliminate the otherwise inevitable and irreversible negative effects of TBI by directly targeting the associated antigens in cerebrospinal fluid (CSF).
Halberd's nasal spray employs a patent-pending blend of three active ingredients designed to timely address and block the excess production of certain identified inflammatory cytokines and neurotransmitters triggered by head trauma. Excess quantities of these elements are associated with irreversible brain injury. The testing at MSU will evaluate the importance of the timely application of Halberd's nasal spray within hours of a traumatic brain injury to mitigate the otherwise inevitable long-term neurodegeneraton often leading to not just TBI, but also to Alzheimer's Disease, Parkinson's Disease, Epileptic seizures, PTSD, etc.
Halberd's early treatment nasal spray product has the potential for wide acceptance by contact sports participants, first responders, trauma centers and the military. Following successful completion of these pre-clinical tests, Halberd intends to immediately seek expeditious approval of the treatment by the FDA and other regulatory bodies throughout the world to enable sale and distribution within the United States as well as other potential world markets. As previously reported, Halberd has already engaged experts for this pursuit with the FDA.
To get the latest news on Halberd's exciting developments, subscribe by submitting this.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About Mississippi State University College of Veterinary Medicine (CVM).
Mississippi State University College of Veterinary Medicine (MSU CVM) was founded in 1974 The CVM has a total of six locations and serves all 82 counties in Mississippi as well as the entire Southeastern United States. The College's main campus is in Starkville and includes the Wise Center, which houses its main teaching hospital, the Animal Health Center. The MSU CVM Department of Comparative Biomedical Sciences faculty and staff represent the basic scientific disciplines required for education of veterinarians. MSU CVM is committed to an ethical approach to treating animals with a genuine passion and drive.
HALB-Halberd’s Successful Completion of Sampling Phase Marks Major Milestone for Project at Mississippi State University (MSU)
Press Release | 08/22/2023
Novel Nasal Spray for Traumatic Brain Injury Effects Poised to Demonstrate Efficacy in Patent-Pending Product
JACKSON CENTER, PA / ACCESSWIRE / August 22, 2023 / Halberd Corporation (OTC PINK:HALB) announced Mississippi State University (MSU) has finalized the collection of tissue samples from a quantity of the planned test subjects. This enables MSU to proceed with its pre-clinical model to study endpoints for Halberd's groundbreaking patent-pending nasal spray's ability to mitigate the effects of traumatic brain injury (TBI). The analysis of these tissue samples can now proceed to examine and quantify the presence of certain markers related to brain damage and to assess the effectiveness of the nasal spray treatment. The nasal spray is designed to eliminate the otherwise inevitable and irreversible negative effects of TBI by directly targeting the associated antigens in cerebrospinal fluid (CSF).
Halberd's nasal spray employs a patent-pending blend of three active ingredients designed to timely address and block the excess production of certain identified inflammatory cytokines and neurotransmitters triggered by head trauma. Excess quantities of these elements are associated with irreversible brain injury. The testing at MSU will evaluate the importance of the timely application of Halberd's nasal spray within hours of a traumatic brain injury to mitigate the otherwise inevitable long-term neurodegeneraton often leading to not just TBI, but also to Alzheimer's Disease, Parkinson's Disease, Epileptic seizures, PTSD, etc.
Halberd's early treatment nasal spray product has the potential for wide acceptance by contact sports participants, first responders, trauma centers and the military. Following successful completion of these pre-clinical tests, Halberd intends to immediately seek expeditious approval of the treatment by the FDA and other regulatory bodies throughout the world to enable sale and distribution within the United States as well as other potential world markets. As previously reported, Halberd has already engaged experts for this pursuit with the FDA.
To get the latest news on Halberd's exciting developments, subscribe by submitting this.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About Mississippi State University College of Veterinary Medicine (CVM).
Mississippi State University College of Veterinary Medicine (MSU CVM) was founded in 1974 The CVM has a total of six locations and serves all 82 counties in Mississippi as well as the entire Southeastern United States. The College's main campus is in Starkville and includes the Wise Center, which houses its main teaching hospital, the Animal Health Center. The MSU CVM Department of Comparative Biomedical Sciences faculty and staff represent the basic scientific disciplines required for education of veterinarians. MSU CVM is committed to an ethical approach to treating animals with a genuine passion and drive.
HALB-Halberd’s Successful Completion of Sampling Phase Marks Major Milestone for Project at Mississippi State University (MSU)
Press Release | 08/22/2023
Novel Nasal Spray for Traumatic Brain Injury Effects Poised to Demonstrate Efficacy in Patent-Pending Product
JACKSON CENTER, PA / ACCESSWIRE / August 22, 2023 / Halberd Corporation (OTC PINK:HALB) announced Mississippi State University (MSU) has finalized the collection of tissue samples from a quantity of the planned test subjects. This enables MSU to proceed with its pre-clinical model to study endpoints for Halberd's groundbreaking patent-pending nasal spray's ability to mitigate the effects of traumatic brain injury (TBI). The analysis of these tissue samples can now proceed to examine and quantify the presence of certain markers related to brain damage and to assess the effectiveness of the nasal spray treatment. The nasal spray is designed to eliminate the otherwise inevitable and irreversible negative effects of TBI by directly targeting the associated antigens in cerebrospinal fluid (CSF).
Halberd's nasal spray employs a patent-pending blend of three active ingredients designed to timely address and block the excess production of certain identified inflammatory cytokines and neurotransmitters triggered by head trauma. Excess quantities of these elements are associated with irreversible brain injury. The testing at MSU will evaluate the importance of the timely application of Halberd's nasal spray within hours of a traumatic brain injury to mitigate the otherwise inevitable long-term neurodegeneraton often leading to not just TBI, but also to Alzheimer's Disease, Parkinson's Disease, Epileptic seizures, PTSD, etc.
Halberd's early treatment nasal spray product has the potential for wide acceptance by contact sports participants, first responders, trauma centers and the military. Following successful completion of these pre-clinical tests, Halberd intends to immediately seek expeditious approval of the treatment by the FDA and other regulatory bodies throughout the world to enable sale and distribution within the United States as well as other potential world markets. As previously reported, Halberd has already engaged experts for this pursuit with the FDA.
To get the latest news on Halberd's exciting developments, subscribe by submitting this.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About Mississippi State University College of Veterinary Medicine (CVM).
Mississippi State University College of Veterinary Medicine (MSU CVM) was founded in 1974 The CVM has a total of six locations and serves all 82 counties in Mississippi as well as the entire Southeastern United States. The College's main campus is in Starkville and includes the Wise Center, which houses its main teaching hospital, the Animal Health Center. The MSU CVM Department of Comparative Biomedical Sciences faculty and staff represent the basic scientific disciplines required for education of veterinarians. MSU CVM is committed to an ethical approach to treating animals with a genuine passion and drive.